Palatin Technologies INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Palatin Technologies reported a $17.3 million net loss for fiscal year 2025, faces delisting from NYSE American, but secured a significant collaboration with Boehringer Ingelheim and advanced multiple drug candidates.
NASDAQ
Palatin Technologies reports a net loss of $29.7 million for fiscal year 2024 and expresses substantial doubt about its ability to continue as a going concern.